Published: 19 March 2026
Author(s): Jens Vikse, Marco Lanzillotta, Elisabetta Goni, Bjørg-Tilde Svanes Fevang, Øyvind Midtvedt, Jasmin Mahajne, Veronica Batani, Giovanni Benanti, Georg Beyer, Lorenzo Dagna, Øyvind Molberg, Katrine Brække Norheim, Cathrine Brunborg, Ulf Schönermarck, Ivonne Regel, Julia Mayerle, Emanuel Della-Torre, Anna-Maria Hoffmann-Vold
Section: Original Article
While the rituximab-treated patients in this study had more severe IgG4-RD than the glucocorticoid-treated comparators, treatment with rituximab was associated with similar effectiveness endpoints, while significantly reducing glucocorticoid use.
